Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
- 1 December 2008
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 9 (12), 1166-1172
- https://doi.org/10.1016/s1470-2045(08)70305-x
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline SummaryJournal of Oncology Practice, 2007
- Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized TrialObstetrical & Gynecological Survey, 2007
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Zoledronic acid improves femoral head sphericity in a rat model of perthes diseaseJournal of Orthopaedic Research, 2005
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Thrombotic Thrombocytopenic Purpura Associated with ClopidogrelNew England Journal of Medicine, 2000